In the inaugural episode of Baringa's Pharmaceutical and Life Sciences podcast, Baringa’s expert in Pharmaceuticals and Life Sciences, Josh Elliott is joined by Eric Walk, Chief Medical Officer at PathAI, to explore how strategic partnerships between digital and AI, and biopharma organisations are shaping the future of precision medicine.

Discover how to become a biopharma partner of choice, by overcoming key challenges faced when partnering with digital and AI organisations.

Listen on Spotify or on Amazon Music

View a transcript of this podcast here

 

About our host:

Josh Elliott

Josh Elliott, expert in Pharmaceuticals and Life Sciences

Josh helps global BioPharma organisations navigate their most complex business transformations with his experience ranging from pre-clinical research through to commercialisation. His specialism and passion is in helping his BioPharma clients optimise how they strategically partner with the wider ecosystem to maximise outcomes, having advised multiple market-leading strategic alliances and helped set up partnering operating models for organisations as a whole.  His breadth of business transformation, R&D content knowledge, and people change expertise enables him to tailor a wide-range of tools and methods to the specific problem to solve, whether this involves utilising innovative digital technologies, embedding operational excellence and agility, or embedding behavioural change.

 

About our guest:

Eric Walk

Eric Walk, Chief Medical Officer, PathAI

Dr. Eric Walk is head of the Medical group at PathAI, overseeing the Precision Medicine, Clinical Science, Quality and Regulatory teams. He has over 20 years of experience in precision medicine, oncology drug development and IVD companion diagnostics development. Prior to joining PathAI, Eric was Chief Medical and Scientific Officer at Roche Tissue Diagnostics/Ventana Medical Systems, where he led Medical & Scientific Affairs, overseeing the validation and FDA clearance/approval of multiple 510k and PMA IVD assays, companion diagnostics and digital pathology algorithms. Eric began his industry career at Novartis Oncology, where he held positions in Early Clinical Development and Translational Medicine, working to implement biomarker and precision medicine strategies for early and late stage targeted oncology therapeutics.

Related Insights

Subscribe to our Pharmaceuticals and Life Sciences reports

The latest industry news and trending topics direct to your inbox.

Subscribe now

Contact us

Find out what we can do for you...

Get in touch